Anti-CDKN2A monoclonal antibody

Pre-made anti-CDKN2A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CDKN2A/CDKN2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T16452-Ab-1/ GM-Tg-hg-T16452-Ab-2Anti-Human CDKN2A monoclonal antibodyHuman
GM-Tg-rg-T16452-Ab-1/ GM-Tg-rg-T16452-Ab-2Anti-Rat CDKN2A monoclonal antibodyRat
GM-Tg-mg-T16452-Ab-1/ GM-Tg-mg-T16452-Ab-2Anti-Mouse CDKN2A monoclonal antibodyMouse
GM-Tg-cynog-T16452-Ab-1/ GM-Tg-cynog-T16452-Ab-2Anti-Cynomolgus/ Rhesus macaque CDKN2A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T16452-Ab-1/ GM-Tg-felg-T16452-Ab-2Anti-Feline CDKN2A monoclonal antibodyFeline
GM-Tg-cang-T16452-Ab-1/ GM-Tg-cang-T16452-Ab-2Anti-Canine CDKN2A monoclonal antibodyCanine
GM-Tg-bovg-T16452-Ab-1/ GM-Tg-bovg-T16452-Ab-2Anti-Bovine CDKN2A monoclonal antibodyBovine
GM-Tg-equg-T16452-Ab-1/ GM-Tg-equg-T16452-Ab-2Anti-Equine CDKN2A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T16452-Ab-1/ GM-Tg-hg-T16452-Ab-2; GM-Tg-rg-T16452-Ab-1/ GM-Tg-rg-T16452-Ab-2;
GM-Tg-mg-T16452-Ab-1/ GM-Tg-mg-T16452-Ab-2; GM-Tg-cynog-T16452-Ab-1/ GM-Tg-cynog-T16452-Ab-2;
GM-Tg-felg-T16452-Ab-1/ GM-Tg-felg-T16452-Ab-2; GM-Tg-cang-T16452-Ab-1/ GM-Tg-cang-T16452-Ab-2;
GM-Tg-bovg-T16452-Ab-1/ GM-Tg-bovg-T16452-Ab-2; GM-Tg-equg-T16452-Ab-1/ GM-Tg-equg-T16452-Ab-2
Products NameAnti-CDKN2A monoclonal antibody
Formatmab
Target NameCDKN2A
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CDKN2A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T16452-Ag-1Recombinant multi-species CDN2A/ ARF/ CDKN2A protein
    ORF Viral VectorpGMAD000002human CDKN2A Adenovirus plasmid
    ORF Viral VectorvGMAD000002human CDKN2A Adenovirus particle
    ORF Viral VectorpGMLPm000244mouse Cdkn2a Lentivirus plasmid
    ORF Viral VectorvGMLPm000244mouse Cdkn2a Lentivirus particle


    Target information

    Target IDGM-T16452
    Target NameCDKN2A
    Gene ID1029
    Gene Symbol and SynonymsARF,CDK4I,CDKN2,CDKN2A,CMM2,INK4,INK4A,MLM,MTS-1,MTS1,P14,P14ARF,P16,P16-INK4A,P16INK4,P16INK4A,P19,P19ARF,TP16
    Uniprot AccessionP42771, Q8N726
    Uniprot Entry NameARF_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseProstate Cancer, Skin cancer - melanoma
    Gene EnsemblENSG00000147889
    Target ClassificationN/A

    The target: CDKN2A, gene name: CDKN2A, also named as ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16. This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.